drugset / Trial / NCT01633723
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
RandomizedFactorialTriple-blindTreatment
Summary
DA-6886\_IBS\_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after oral administration in healthy male subjects.
Timeline
- Start
- 2012-08
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-6886 | Small molecule | 1 mg | Oral |
| Subject | DA-6886 | Small molecule | 2.5 mg | Oral |
| Subject | DA-6886 | Small molecule | 5 mg | Oral |
| Subject | DA-6886 | Small molecule | 10 mg | Oral |
| Subject | DA-6886 | Small molecule | 20 mg | Oral |